Meeting News

Immunotherapy combination ‘new standard of care’ in metastatic renal cell carcinoma

November 3, 2017
MIAMI The combination of ipilimumab and nivolumab is an effective standard frontline treatment of patients with metastatic renal cell carcinoma…
Meeting News

Lenvatinib plus pembrolizumab active in metastatic clear cell renal cell carcinoma

November 3, 2017
MIAMI — The combination of lenvatinib and pembrolizumab exhibited antitumor activity among patients with metastatic clear cell renal cell…
Meeting NewsVideo

VIDEO: Symposium offers research, mentorship opportunities

November 3, 2017
MIAMI Toni K. Choueiri, MD, from Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center, interviews two members of the Scientific…
Meeting News

Pretreatment neutrophil-to-lymphocyte ratio predicts outcomes in metastatic renal cell carcinoma

November 3, 2017
MIAMI — Lower pretreatment neutrophil-to-lymphocyte ratios appeared associated with longer PFS and OS among patients with metastatic renal cell…
Meeting NewsVideo

VIDEO: Geographic location plays role in renal cell carcinoma outcomes

November 3, 2017
MIAMI Toni K. Choueiri, MD, from Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center, discusses how treatment center location may…
Meeting News

Private insurance associated with longer survival in metastatic renal cell carcinoma

November 3, 2017
MIAMI — An analysis of patients with metastatic renal cell carcinoma treated during the targeted therapy era showed those with private…
Meeting News

Nivolumab active in metastatic non-clear cell renal cell carcinoma

November 3, 2017
MIAMI — Nivolumab monotherapy demonstrated antitumor activity in a heterogenous population of patients with non-clear cell renal cell…
Meeting News

Secondary data analysis offers ‘high-impact’ approach to improving patient care

November 3, 2017
MIAMI Secondary data analysis enables researchers to provide high-impact data; however, implementation of this approach can be complex, Maxine Sun